Novel prophylactic and therapeutic vaccine against tuberculosis

Vaccine. 2009 May 26;27(25-26):3267-70. doi: 10.1016/j.vaccine.2009.01.064. Epub 2009 Feb 5.


We have developed a novel tuberculosis (TB) vaccine; a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and interleukin 12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-envelope and -liposome (HSP65+IL-12/HVJ). This vaccine provided therapeutic efficacy as well as remarkable protective efficacy via CD8(+) T and CD4(+) T cells in murine models compared with the saline controls, on the basis of CFU of number of multi-drug resistant TB (MDR-TB), and survival of extremely drug resistant TB (XDR-TB) challenged mice. Furthermore, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis. This vaccine exerted therapeutic efficacy (survival and immune responses) in the TB-infected monkeys. These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacterial Proteins / genetics
  • Bacterial Proteins / immunology*
  • CD8 Antigens / immunology
  • Chaperonin 60
  • Chaperonins / genetics
  • Chaperonins / immunology*
  • Drug Resistance, Multiple, Bacterial
  • Interleukin-12 / genetics
  • Interleukin-12 / immunology*
  • Lung / microbiology
  • Macaca fascicularis
  • Mice
  • Tuberculosis / therapy*
  • Tuberculosis Vaccines / immunology
  • Tuberculosis Vaccines / therapeutic use*
  • Vaccination
  • Vaccines, DNA / immunology
  • Vaccines, DNA / therapeutic use*


  • Bacterial Proteins
  • CD8 Antigens
  • Chaperonin 60
  • Tuberculosis Vaccines
  • Vaccines, DNA
  • heat-shock protein 65, Mycobacterium
  • Interleukin-12
  • Chaperonins